CG Oncology initiates EAP for Cretostimogene Grenadenorepvec in U.S.

CG Oncology announced that it has initiated an Expanded Access Program EAP for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer NMIBC who are unresponsive to Bacillus Calmette-Guerin BCG and meet certain program eligibility criteria. The first patient has been dosed in the EAP and enrollment in the study is ongoing…”Bladder cancer is a highly recurrent disease with few treatment options available to patients,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “This program reflects our commitment to patients afflicted with NMIBC and our desire to ensure that they have efficient access to cretostimogene, our novel oncolytic immunotherapy candidate.” “Navigating NMIBC can be a journey filled with uncertainties, especially given how frequently bladder cancer recurs,” said Andrea Maddox-Smith, CEO of the Bladder Cancer Advocacy Network BCAN . “At BCAN, patients are at the forefront of everything we do. Despite the progress being made to find new treatments, there are times when patients have exhausted all approved treatment options, and they are not eligible for a traditional clinical trial. Expanded Access Programs represent tremendous hope for these patients and their families, by allowing them access to investigational drugs that they would not otherwise have available to them.”